Letter: Persisting with persistence—A caution as an outcome measure in inflammatory bowel disease: Authors' reply-Reference-Cited by-同舟云学术

Letter: Persisting with persistence—A caution as an outcome measure in inflammatory bowel disease: Authors' reply

Published:2024-06-24 Issue:3 Volume:60 Page:427-428
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Yiu Tsz Hong¹^ORCID,Ko Yanna²³,Pudipeddi Aviv³^ORCID,Natale Patrizia¹⁴⁵,Leong Rupert W.³

Affiliation:

1. School of Public Health, University of Sydney Sydney New South Wales Australia

2. Campbelltown and Camden Hospitals, Canterbury Hospital, Western Sydney University Sydney New South Wales Australia

3. Gastroenterology and Liver Services, Concord Repatriation General Hospital Sydney New South Wales Australia

4. Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE‐J) University of Bari Aldo Moro Bari Italy

5. Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences University of Foggia Foggia Italy

Abstract

LINKED CONTENTThis article is linked to Yiu et al papers. To view these articles, visit https://doi.org/10.1111/apt.18006 and https://doi.org/10.1111/apt.18114

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18136

Reference6 articles.

1. Letter: persisting with persistence—a caution as an outcome measure in inflammatory bowel disease;Rao V;Aliment Pharmacol Ther,2024

2. Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease

3. Knowledge and attitudes towards the use of histological assessments in ulcerative colitis by gastroenterologists vs pathologists

4. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD

5. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases